scholarly journals Prescription Pattern of Primary Osteoarthritis in Tertiary Medical Centre

2017 ◽  
Vol 07 (04) ◽  
pp. 037-042
Author(s):  
Sowmya Sham Kanneppady ◽  
Sham Kishor Kanneppady ◽  
Vijaya Raghavan ◽  
Aung Myo Oo ◽  
Ohn Mar Lwin
Keyword(s):  
Vitamin D ◽  
Chondroitin Sulfate ◽  
Musculoskeletal Disorders ◽  
Therapeutic Agents ◽  
Medical Centre ◽  
Fixed Dose ◽  
Age Group ◽  
Prescription Pattern ◽  
Treatment Regimens ◽  
Dose Combination

Abstract Objectives: Osteoarthritis (OA) is one of the commonest joint/musculoskeletal disorders, affecting the middle aged and elderly, although younger people may be affected as a result of injury or overuse. The study aimed to analyze the data, evaluate the prescription pattern and rationality of the use of drugs in the treatment of primary OA with due emphasis on the available treatment regimens. Materials and methods: Medical case records of patients suffering from primary OA attending the department of Orthopedics of a tertiary medical centre were the source of data. The study was carried out prospectively for a period of 20 months (from December 2012 to July 2014). Results: 296 case records were collected in which the total number of drugs prescribed were 550. OA was more common in females (51.7%) and was more prevalent in the age group of 30–40 years (39%). Out of 550 drugs prescribed, Aceclofenac was the most frequently prescribed NSAID (29%) followed by Diclofenac (23%). Nimesulide and Paracetamol was the most commonly prescribed fixed dose combination (53). Among gastroprotectives, Ranitidine figured in 66 prescriptions. Glucocorticoids were prescribed orally and intraarticularly in 17 and 14 cases respectively. Dietary supplements like Calcium+Vitamin D (42) and Glucosamine Sulfate + Chondroitin Sulfate complex (19) were also prescribed. Conclusion: The above study highlights the rational use of therapeutic agents for primary OA.

scholarly journals Outcome of Fixed Dose Combination of Tenofovir, Lamivudine and Dolutegravir in Rural HIV Care Facility in Nigeria

2021 ◽  
Vol 11 (12) ◽  
pp. 1-8
Author(s):  
Ogbuagu Chukwuanugo Nkemakonam ◽  
Ogbuagu Ekenechukwu Nkiloka ◽  
Okoh Emeka Emmanuel
Keyword(s):  
Viral Load ◽  
Combination Therapy ◽  
Sub Saharan Africa ◽  
Fixed Dose Combination ◽  
Hiv Care ◽  
Fixed Dose ◽  
People Living With Hiv ◽  
Age Group ◽  
Cd4 Counts ◽  
Dose Combination

Background: Antiretroviral therapy (ART) has significantly increased the lifespan of people living with HIV. Currently, fixed dosed combination therapy (Tenofovir, Lamivudine, and Dolutegravir) is being introduced in most countries in the Sub- Saharan Africa. There is need for a clinical and immunological assessment of HIV patients transitioned to this new therapy over a period of 2 years. Objectives: To determine the proportion of patients whose viral load was suppressed to <20 copies/ml following two years therapy with Dolutegravir-based fixed-dose combination therapy. Methods: This retrospective cohort study was carried out in a Comprehensive Healthcare Centre (CHC), a facility affiliated with Nnamdi Azikiwe University Teaching Hospital Nigeria. The primary outcome measure was the proportion of patients whose viral load was suppressed to <20 copies/ml. The plasma viral load (HIV-RNA) assay was done using real time PCR and CD4+ T- lymphocyte (CD4+) counts were estimated using Flow Cytometry. The exclusion criteria were patients who has invalid data base and patients with comorbidities associated with HIV. Results: A total of 537 HIV1 sero-positive patients were enrolled for ART care over a period of 2 years (2017-2018). Females in the age group (41-50 years) constituted the bulk (36.9%) of the patients whilst the least (5.3%) were males in the age group (8 to 30 years). The mean CD4 count of patients was 847.35cells/mm3. More females (45.9%) had CD4+counts over 500cells/mm3 whilst the percentage of males with CD4+ cell counts over 500cells/mm3 was 43.8%. Majority, 405 constituting 75.4% of the patients have suppressed viral load (<20 copies/ml) signifying that the centre is achieving success with respect to service delivery and ART. Patients with unsuppressed viral loads were more among Females with CD4+ counts in the range of 200-499 cells/mm3and this may be as a result of other associated factors which will be elucidated in future studies. Conclusion: Dolutegravir-based fixed-dose combination therapy suppressed viral load to <20 copies/ml in more than 75% of patients receiving the therapy. Enhanced adherence and effective doctor-patient relationship could be associated with the viral suppression observed in this study. Key words: Immunology, virology, HIV Outcome, Dolutegravir-based combination therapy, anti retroviral therapy.

scholarly journals Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy

2017 ◽  
Vol 7 (3) ◽  
pp. 265-279 ◽  
Author(s):  
Siegfried Segaert ◽  
Neil H. Shear ◽  
Andrea Chiricozzi ◽  
Diamant Thaçi ◽  
Jose-Manuel Carrascosa ◽  
...  
Keyword(s):  
Vitamin D ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Immunomodulatory Effects ◽  
Dose Combination ◽  
Anti Inflammatory ◽  
Vitamin D Analogue

scholarly journals Efficacy and Safety of Triple Drug Fixed-Dose Combination of Telmisartan, Amlodipine and Hydrochlorthiazide in the Management of Hypertension

2015 ◽  
Vol 16 (1) ◽  
pp. 18-22
Author(s):  
Faruqui A Arif ◽  
A Amlaselvam ◽  
Renuka Sriram
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Fixed Dose Combination ◽  
Antihypertensive Drug Therapy ◽  
Fixed Dose ◽  
Age Group ◽  
Optimal Management ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination

Effective BP control is far away from reality in many patients in spite of advancements in many classes of antihypertensive drug therapy. Use of triple drug combination in the management of hypertension have already been established, however this study was conducted to evaluate the efficacy and safety of triple drug fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorothiazide 12.5mg. 69 hypertensive patients with seating cuff systolic blood pressure e” 160 mmHg and diastolic blood pressure e”100 mmHg were enrolled in the study. Patients were prescribed to take triple drug fixed dose combination for 120 days. Patients were evaluated on 30th, 60th and 120th days of treatment. There was statistically significant (p<0.0001) decrease in systolic blood pressure from baseline to 30th, 60th and 120th day of treatment mean±SD (166±18.6 mmHg vs.147±16.1, 137±14.7 and 130±13.9 mmHg) respectively. Similar to SBP, decrease in DBP was highly significant (p<0.0001) from the baseline to the 30th, 60th and 120th day of treatment (104±11.5 mmHg vs. 93.7±12.3, 89±10.2 and 84.5±8.98 mmHg respectively). Moreover at the end of the study period of 120 days 85.7% and 87.8% patients of age group >60 years and <60 years respectively achieved the JNC VIII recommended goal. This triple drug fixed dose combination of Telmisartan, Amlodipine and hydrochlorothiazide was found to be effective and safe option for the optimal management of hypertension.DOI: http://dx.doi.org/10.3329/jom.v16i1.22383 J MEDICINE 2015; 16 : 18-22

scholarly journals A study on the prescription pattern of antifungal drugs in the Dermatology Department of a tertiary care teaching hospital in Southern Kerala

2018 ◽  
Vol 8 (1) ◽  
pp. 100
Author(s):  
Parvathy Gopimohan ◽  
Sudha M. J. ◽  
Rathish T. Pillai ◽  
Ramani P. T.
Keyword(s):  
Fungal Infection ◽  
Tertiary Care ◽  
Cost Effective ◽  
Antifungal Drugs ◽  
Fixed Dose ◽  
Dermatology Department ◽  
Prescription Pattern ◽  
Number Of Patients ◽  
Dose Combination ◽  
Cutaneous Fungal Infection

Background: Skin disorders form 2% of total Out Patient Department consultations worldwide. But no such data is available from India. Studying prescription pattern is a component of medical audit that help prescribers to provide rational and cost-effective medical care. This study is about the prescription pattern of antifungals in this institution and will help in developing local policies for appropriate use of antifungal drugs. The objective was to study the prescription pattern of antifungals in dermatological diseases.Methods: This is a retrospective study conducted from 1st June 2017 to 30th November 2017 in Dermatology Department. Prescriptions included all newly diagnosed patients with cutaneous fungal infection of both sex who attended Dermatology OPD. Factors considered were sociodemographic parameters, number of patients with combination and monotherapy, number of single topical agents and Fixed Dose Combination (FDC) details of prescribing indicators.Results: 1500 prescriptions were analysed; 500 prescriptions were of fungal infection. 40.2% of the patients were in 18-35 years age group. There were a greater number of males (59.6%) than females (40.4%).Conclusions: The most common oral antifungal used was fluconazole. Terbinafine and clotrimazole were the most commonly used topical agents.

scholarly journals Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients

2014 ◽  
Vol 170 (3) ◽  
pp. 441-450 ◽  
Author(s):  
R Rizzoli ◽  
B Dawson-Hughes ◽  
J-M Kaufman ◽  
P Fardellone ◽  
M L Brandi ◽  
...  
Keyword(s):  
Vitamin D ◽  
Strontium Ranelate ◽  
Vitamin D Insufficiency ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Primary Osteoporosis ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Hydroxyvitamin D ◽  
Dose Combination

ObjectiveThis study aims to investigate the efficacy and safety of oral fixed-dose combination of strontium ranelate 2 g/vitamin D31000 IU daily vs strontium ranelate 2 g daily for correcting vitamin D insufficiency in osteoporosis.DesignA 6-month international, randomized, double-blind, parallel-group, phase 3 study.MethodsA total of 518 men and postmenopausal women aged ≥50 years with primary osteoporosis (T-score ≤−2.5s.d.) and serum 25-hydroxyvitamin D (25(OH)D) >22.5 nmol/l were included. Patients were allocated to strontium ranelate 2 g/vitamin D31000 IU daily (n=413) or strontium ranelate 2 g daily (n=105). The participants received calcium 1 g daily. The primary endpoint was serum 25(OH)D at last post-baseline evaluation during 3 months.ResultsBoth groups were comparable at baseline. Mean baseline of 25(OH)D was 44.1±14.6 nmol/l. After 3 months, the percentage of patients with 25(OH)D ≥50 nmol/l was higher with strontium ranelate/vitamin D3vs strontium ranelate (84 vs 44%,P<0.001; adjusted between-group odds ratio=6.7; 95% CI, 4.2–10.9). The efficacy of the fixed-dose combination on 25(OH)D was maintained at 6 months (86 vs 40%,P<0.001). Mean 25(OH)D was 65.1 and 49.5 nmol/l, respectively, after 3 months and 66.9 and 45.4 nmol/l after 6 months. Physical performance improved in both groups. Falls were 17 and 20% in the strontium ranelate/vitamin D3and strontium ranelate groups respectively. Parathyroid hormone levels were inversely correlated with 25(OH)D. No clinically relevant differences in safety were observed.ConclusionsThis study confirms the efficacy and safety of fixed-dose combination of strontium ranelate 2 g/vitamin D31000 IU for correction of vitamin D insufficiency in osteoporotic patients.

scholarly journals Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Andrea Barranjard Vannucci Lomonte ◽  
Emerson Gimenez ◽  
Antônio Carlos da Silva ◽  
Sebastião Cezar Radominski ◽  
Morton Aaron Scheinberg ◽  
...  
Keyword(s):  
Knee Osteoarthritis ◽  
Chondroitin Sulfate ◽  
Glucosamine Sulfate ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Womac Pain ◽  
Pain Subscale ◽  
Dose Combination ◽  
New Formulation ◽  
Single Blind

Abstract Objectives To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA). Methods In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use. Results Mean reductions of WOMAC pain score were − 35.1 (sd = 23.2) mm in the GS/CS group and − 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the non-inferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events. Conclusions The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile. Trial registration ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).

Sign in / Sign up

Export Citation Format

Share Document